Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors
2.
Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC
3.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
4.
Prostate cancer therapies: AI-based image analysis detects early organ damage
5.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
1.
Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing
2.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
5.
Bridging the Global Divide: Enhancing Psychosocial Care for Cancer Survivors Across Income Settings
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge